carnitine has been researched along with Encephalopathy, Toxic in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carnitine is an essential metabolite that is absorbed from the diet and synthesized in the kidney, liver, and brain." | 2.72 | Neuroprotective Effects of Carnitine and Its Potential Application to Ameliorate Neurotoxicity. ( Latham, LE; Liu, F; Patterson, TA; Slikker, W; Wang, C, 2021) |
| "VPA is widely used for the treatment of generalized epilepsy." | 2.61 | [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy]. ( Araki, M; Mukai, T; Naka, H; Shishido, T; Tokinobu, H; Yamada, H, 2019) |
| "Carnitine is an essential cofactor in the proper metabolism of valproic acid and ammonia elimination." | 2.48 | Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy. ( Mock, CM; Schwetschenau, KH, 2012) |
| "Carnitine is an amino acid derivative that is an essential cofactor in the beta-oxidation of fatty acids." | 2.45 | Carnitine in the treatment of valproic acid-induced toxicity. ( Hantson, P; Lheureux, PE, 2009) |
| " Our results suggest that LC may have great pharmacological potential in protecting against the adverse effects of nickel in the nervous system." | 1.37 | L-carnitine protects against nickel-induced neurotoxicity by maintaining mitochondrial function in Neuro-2a cells. ( He, MD; Li, L; Li, M; Lu, YH; Wang, Y; Xu, SC; Yang, J; Yu, ZP; Zhang, GB; Zhang, YW; Zhong, M; Zhou, Z, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, JE | 1 |
| Kim, JB | 1 |
| Jo, DS | 1 |
| Park, NY | 1 |
| Kim, YH | 1 |
| Lee, HJ | 1 |
| Kim, SH | 2 |
| Son, M | 1 |
| Kim, P | 1 |
| Ryu, HY | 1 |
| Lee, WH | 1 |
| Ryoo, ZY | 1 |
| Lee, HS | 1 |
| Jung, YK | 1 |
| Cho, DH | 1 |
| Khakwani, A | 1 |
| Gannon, D | 1 |
| Latham, LE | 1 |
| Wang, C | 1 |
| Patterson, TA | 1 |
| Slikker, W | 1 |
| Liu, F | 1 |
| Song, X | 1 |
| Fiati Kenston, SS | 1 |
| Kong, L | 1 |
| Zhao, J | 1 |
| Triplett, KE | 1 |
| Murray, R | 1 |
| Anstey, M | 1 |
| Yamada, H | 1 |
| Shishido, T | 1 |
| Mukai, T | 1 |
| Araki, M | 1 |
| Naka, H | 1 |
| Tokinobu, H | 1 |
| Lheureux, PE | 1 |
| Hantson, P | 1 |
| He, MD | 1 |
| Xu, SC | 1 |
| Lu, YH | 1 |
| Li, L | 1 |
| Zhong, M | 1 |
| Zhang, YW | 1 |
| Wang, Y | 1 |
| Li, M | 1 |
| Yang, J | 1 |
| Zhang, GB | 1 |
| Yu, ZP | 1 |
| Zhou, Z | 1 |
| Mock, CM | 1 |
| Schwetschenau, KH | 1 |
| Binienda, ZK | 2 |
| Ali, SF | 2 |
| Virmani, A | 2 |
| Amato, A | 2 |
| Salem, N | 2 |
| Przybyla, BD | 2 |
| Robinson, BL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study[NCT05881928] | Phase 4 | 50 participants (Anticipated) | Interventional | 2023-07-25 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for carnitine and Encephalopathy, Toxic
| Article | Year |
|---|---|
L-carnitine supplementation as a potential therapy for suspected hyperammonaemic encephalopathy.
Topics: Adult; Anticonvulsants; Blood Chemical Analysis; Carnitine; Cerebral Palsy; Dietary Supplements; Epi | 2019 |
Neuroprotective Effects of Carnitine and Its Potential Application to Ameliorate Neurotoxicity.
Topics: Animals; Carnitine; Central Nervous System; Humans; Molecular Structure; Neuroprotective Agents; Neu | 2021 |
Molecular mechanisms of nickel induced neurotoxicity and chemoprevention.
Topics: Animals; Carnitine; Cell Line; Chemoprevention; Disease Models, Animal; DNA Damage; DNA, Mitochondri | 2017 |
[Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
Topics: Aged; Ammonia; Anticonvulsants; Biomarkers; Cardiomyopathies; Carnitine; Consciousness Disorders; Ep | 2019 |
Carnitine in the treatment of valproic acid-induced toxicity.
Topics: Animals; Anticonvulsants; Antidotes; Carnitine; Chemical and Drug Induced Liver Injury; Energy Metab | 2009 |
Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy.
Topics: Carnitine; Humans; Hyperammonemia; Neurotoxicity Syndromes; Valproic Acid | 2012 |
5 other studies available for carnitine and Encephalopathy, Toxic
| Article | Year |
|---|---|
Carnitine Protects against MPP
Topics: 1-Methyl-4-phenylpyridinium; Acetylcarnitine; Apoptosis; Carnitine; Cell Line, Tumor; Dopaminergic N | 2022 |
Multifactorial non-cirrhotic hyperammonaemic encephalopathy.
Topics: Acetylcysteine; Aftercare; Anti-Bacterial Agents; Bacteremia; Carnitine; Female; Free Radical Scaven | 2018 |
L-carnitine protects against nickel-induced neurotoxicity by maintaining mitochondrial function in Neuro-2a cells.
Topics: Animals; Carnitine; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Mice; Mitocho | 2011 |
Co-regulation of dopamine D1 receptor and uncoupling protein-2 expression in 3-nitropropionic acid-induced neurotoxicity: neuroprotective role of L-carnitine.
Topics: Animals; Body Temperature; Carnitine; Disease Models, Animal; Drug Interactions; Gene Expression Reg | 2006 |
Effects of L-carnitine pretreatment in methamphetamine and 3-nitropropionic acid-induced neurotoxicity.
Topics: Animals; Antihypertensive Agents; Carnitine; Dopamine Agents; Male; Methamphetamine; Neurotoxicity S | 2006 |